GEN-MKT-18-7897-A
Mar 20, 2019 | Blogs, Software, Technology | 0 comments
Does your laboratory have multiple scientists who require access to crucial software at the same time? Are some of those scientists only part-time users?
Purchasing separate licenses for each person can be expensive, especially if some of your users only occasionally need access. So just how many software licenses should you purchase? No one wants to pay for something you don’t need, but you also don’t want to hinder your lab’s productivity by limiting access to critical resources. The concurrent software licensing model can help.
Unlike a node-locked license, where the software program and its license are tied to a specific computer, a concurrent license is obtained from a central server. Much like borrowing a book from a public library, when the user starts the software application on their computer, a license is borrowed from the main server over the network. When the user is finished, they close the application, and the license is returned to the server for someone else to use.
The question becomes: How many, and what type of license should you buy? If a workstation controls a mass spectrometer, it must use a node-locked license. But if the software is only used for data processing, then a concurrent license might be a more economical choice. So how many concurrent licenses should you purchase? Because concurrent licenses are checked out and not permanently assigned, it becomes a question of how many user-computer combinations need access to the application concurrently, or at the same time, not in total.
This calculation exercise will help you decide:
The concurrent licensing model can be quite economical, particularly for laboratories with multiple casual users. Just a few licenses can provide access for many part-time users. But what happens if you need access to the software while traveling? While a node-locked license would certainly suffice, this can be an expensive solution for part-time users. With the concurrent licensing model, users are allowed to borrow a concurrent license to work offline. Upon return, the license is simply checked back in again. To safeguard against a forgotten license that is checked-out for too long, the license “times out” and is checked back in automatically after 7 days.
Hosting concurrent licenses on a central server has many benefits for IT departments too since set-up and deployment is much easier than deploying multiple node-locked licenses. New licenses can be easily added as your user base grows. For ultimate flexibility, concurrent licenses can be purchased one-by-one so the optimal number of licenses can be achieved for each individual laboratory.
To learn more about concurrent software licensing from SCIEX, and how it can be an efficient and economical solution for your laboratory, read our latest white paper. Or, contact our software sales specialist.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network